You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

CLINICAL TRIALS PROFILE FOR VIIBRYD


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Viibryd

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01473381 ↗ Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed Forest Laboratories Phase 4 2011-12-01 The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
NCT01473394 ↗ Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder Completed Forest Laboratories Phase 4 2011-12-01 The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
NCT01573598 ↗ Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed Forest Laboratories Phase 4 2012-04-01 Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01574183 ↗ Vilazodone Treatment for Marijuana Dependence Completed National Institute on Drug Abuse (NIDA) Phase 2 2012-08-01 Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
NCT01574183 ↗ Vilazodone Treatment for Marijuana Dependence Completed Medical University of South Carolina Phase 2 2012-08-01 Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
NCT01608295 ↗ Vilazodone for Treatment of Geriatric Depression Completed Forest Laboratories Phase 4 2012-07-01 The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
NCT01608295 ↗ Vilazodone for Treatment of Geriatric Depression Completed University of California, Los Angeles Phase 4 2012-07-01 The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Viibryd

Condition Name

Condition Name for Viibryd
Intervention Trials
Major Depressive Disorder 9
Comorbidity 1
Healthy 1
Hot Flushes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Viibryd
Intervention Trials
Depressive Disorder, Major 10
Depressive Disorder 10
Depression 10
Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Viibryd

Trials by Country

Trials by Country for Viibryd
Location Trials
United States 134
Ukraine 5
Canada 4
Serbia 4
Finland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Viibryd
Location Trials
Texas 7
New York 7
Florida 7
California 7
Virginia 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Viibryd

Clinical Trial Phase

Clinical Trial Phase for Viibryd
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Viibryd
Clinical Trial Phase Trials
Completed 13
Withdrawn 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Viibryd

Sponsor Name

Sponsor Name for Viibryd
Sponsor Trials
Forest Laboratories 13
Medical University of South Carolina 1
University of California, Los Angeles 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Viibryd
Sponsor Trials
Industry 13
Other 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.